R&D | May 23, 2026
WACKER launches contract research services to accelerate next-gen RNA & DNA therapies
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Eye care major expands network to 288 facilities across 10 countries after adding 57 new centres during FY26
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza
The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
The competition received over 42 entries from nursing colleges across Maharashtra
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
